|
Today's News Releases
|
Home | Submit Press Release | Advertise | Submit Website
(IndustryNews247.Com, September 03, 2019 ) Market Overview
• Chronic Immune Thrombocytopenia (chronic ITP) is an autoimmune disorder in which patients produce antiplatelet autoantibodies and specialized white blood cells that destroy their blood platelets and, in some cases, damage their megakaryocytes, causing a decrease in platelet production.
Market Dynamics:
• Growing demand for therapeutics for the treatment of rare blood related disorders, and increasing number of products approved by the Food and Drug Administration are some of the major factors driving the growth of the chronic immune thrombocytopenia (ITP) market globally. According to National Organization of Rare Disorders (NORD), the incidence of ITP among adults in the USA is estimated to be 3.3 per 100,000 adults/year. The prevalence is 9.5 cases per 100,000. The incidence of ITP increases with age and is more common over the age of 60. Among adults (age 30-60) diagnosed with chronic ITP, there are 2.6 cases among women for every case involving a male.
• In addition, increasing drugs in pipeline offers growth opportunities in the chronic immune thrombocytopenia (ITP) market. Argenx’s Efgartigimod is currently (August 2019) tested in Phase 2 clinical trials in immune thrombocytopenia (ITP). Rigel Pharmaceuticals, Inc. manufactures drugs for treatment of rare diseases, immune, hematologic disorders, and cancer. Phase 1 study of R835 and Phase 3 study with fostamatinib in autoimmune hemolytic anemia are major pipelines of the company.
Market Segmentation:
• On the basis of drug class, the global chronic immune thrombocytopenia market is segmented into Immunoglobulin, Thrombopoetin (TPO) Receptor Agonist, Steroids, Platlet Stimulating Agents, and others. Among these, Steroids holds significant market share in 2018 and estimated to grow at a CAGR of 5.74% during the forecast period.
• Chronic ITP is cured either when the platelet count falls below 30,000, or when there is bleeding. A steroid (such as prednisone) is the first treatment; if steroids do not keep the platelet count above 50,000, then it is treated with intravenous gamma globulin. If these treatments are not effective and the platelet count remains dangerously low or there is bleeding, other options such as removal of the spleen (splenectomy), treatment with rituximab (Rituxan), Romiplostim (Nplate) or Eltrombopag (Promacta, Revolade) are preferred. If these initial treatments aren't effective, tranfusions, fostamatinib (Tavalisse), danazol (Danocrine) or immune-suppressing medications (such as azathioprine (Imuran), cyclophosphamide (Cytoxan, Neosar), or vincristine (Oncovin and others)) may be recommended. Combinations of these treatments may be effective when individual treatments are not.
Geographical Analysis
• According to the National Organization for Rare Disorders (NORD), the prevalence of immune thrombocytopenia among adults in the US is estimated to be 3.3 per 100,000 adults/year. In the United States, an estimated 30,000 new cases of ITP are diagnosed each year. Approximately 70% of adults with ITP are women, and 70 percent of these women are under the age of 40 when diagnosed.
• The Europe Chronic ITP market is also growing at a significant CAGR during the forecast period, due to increasing cases of chronic ITP coupled with rising research activities for the treatment of chronic ITP. The European Medicines Agency (EMEA) has recognized chronic immune thrombocytopenia (ITP) as an orphan disease, with nearly 50,000 adult patients with chronic ITP in the European Union.
Competitive Landscape
Some of the major players in the chronic immune thrombocytopenia market are:
• Novartis AG,
• Dova Pharmaceuticals,
• F.Hoffmann-La Roche Ltd.,
• Others
View full sample report: https://www.datamintelligence.com/research-report/chronic-immune-thrombocytopenia-market
Download free sample: https://www.datamintelligence.com/download-sample/chronic-immune-thrombocytopenia-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com
|
|
|
Industrial News TV
|